|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:CEO
|
Sharvil Patel
|
|
gptkbp:developedBy
|
gptkb:ZyCoV-D
|
|
gptkbp:focusesOn
|
gptkb:diabetes
infectious diseases
oncology
vaccines
women's health
dermatology
gastroenterology
nephrology
pain management
cardiovascular diseases
autoimmune diseases
nutraceuticals
respiratory diseases
anti-infectives
biologicals
CNS disorders
|
|
gptkbp:formerName
|
gptkb:Cadila_Healthcare
|
|
gptkbp:foundedBy
|
gptkb:Ramanbhai_Patel
|
|
gptkbp:foundedYear
|
1952
|
|
gptkbp:hasResearchCenter
|
gptkb:Mumbai
gptkb:Ahmedabad
gptkb:Vadodara
|
|
gptkbp:headquartersLocation
|
gptkb:Ahmedabad,_Gujarat,_India
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Zydus Lifesciences
|
|
gptkbp:industry
|
pharmaceuticals
|
|
gptkbp:listedOn
|
gptkb:Forbes_Global_2000
|
|
gptkbp:manufacturingFacilities
|
gptkb:Brazil
gptkb:France
gptkb:Germany
gptkb:India
gptkb:United_States
|
|
gptkbp:numberOfEmployees
|
over 23,000
|
|
gptkbp:operatesIn
|
gptkb:Asia
gptkb:Europe
gptkb:India
gptkb:Latin_America
gptkb:United_States
|
|
gptkbp:parentCompany
|
gptkb:Zydus_Group
|
|
gptkbp:products
|
biosimilars
generic drugs
vaccines
active pharmaceutical ingredients
|
|
gptkbp:publiclyTraded
|
gptkb:NSE
BSE
|
|
gptkbp:revenue
|
over $2 billion (2023)
|
|
gptkbp:stockSymbol
|
gptkb:ZYDUSLIFE
|
|
gptkbp:website
|
https://www.zyduslife.com/
|
|
gptkbp:ZyCoV-D
|
COVID-19 DNA vaccine
|
|
gptkbp:bfsParent
|
gptkb:Pankaj_Patel
gptkb:Pankaj_R._Patel
|
|
gptkbp:bfsLayer
|
5
|